175 related articles for article (PubMed ID: 38264281)
21. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
Araujo-Castro M; García Cano AM; Escobar-Morreale HF; Valderrabano P
Hormones (Athens); 2023 Mar; 22(1):51-59. PubMed ID: 36279032
[TBL] [Abstract][Full Text] [Related]
22. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Tsagarakis S; Terzolo M; Tabarin A; Sahdev A; Newell-Price J; Pelsma I; Marina L; Lorenz K; Bancos I; Arlt W; Dekkers OM
Eur J Endocrinol; 2023 Jul; 189(1):G1-G42. PubMed ID: 37318239
[TBL] [Abstract][Full Text] [Related]
23. Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas.
Araujo-Castro M; Robles Lázaro C; Parra Ramírez P; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
J Endocrinol Invest; 2021 Nov; 44(11):2349-2357. PubMed ID: 33683661
[TBL] [Abstract][Full Text] [Related]
24. The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test.
Arruda M; Mello Ribeiro Cavalari E; Pessoa de Paula M; Fernandes Cordeiro de Morais F; Furtado Bilro G; Alves Coelho MC; de Oliveira E Silva de Morais NA; Choeri D; Moraes A; Vieira Neto L
J Hum Hypertens; 2017 Dec; 32(1):3-11. PubMed ID: 29176595
[TBL] [Abstract][Full Text] [Related]
25. The degree of cortisol secretion is associated with diabetes mellitus and hypertension in patients with nonfunctioning adrenal tumors.
Favero V; Aresta C; Parazzoli C; Cairoli E; Eller-Vainicher C; Palmieri S; Salcuni AS; Arosio M; Persani L; Scillitani A; Morelli V; Chiodini I
Cardiovasc Diabetol; 2023 May; 22(1):102. PubMed ID: 37131218
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of new recommendations for adrenal incidentalomas in the evaluation of excessive cortisol secretion and follow-up.
Ruiz A; Michalopoulou T; Megia A; Näf S; Simón-Muela I; Solano E; Martínez L; Vendrell J
Eur J Clin Invest; 2019 Feb; 49(2):e13048. PubMed ID: 30412278
[TBL] [Abstract][Full Text] [Related]
27. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up.
Papanastasiou L; Alexandraki KI; Androulakis II; Fountoulakis S; Kounadi T; Markou A; Tsiavos V; Samara C; Papaioannou TG; Piaditis G; Kaltsas G
Clin Endocrinol (Oxf); 2017 Apr; 86(4):488-498. PubMed ID: 27992961
[TBL] [Abstract][Full Text] [Related]
28. Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.
Araujo-Castro M; Parra Ramírez P; Robles Lázaro C; García Centeno R; Gracia Gimeno P; Fernández-Ladreda MT; Sampedro Núñez MA; Marazuela M; Escobar-Morreale HF; Valderrabano P
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884211
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study.
Di Dalmazi G; Vicennati V; Garelli S; Casadio E; Rinaldi E; Giampalma E; Mosconi C; Golfieri R; Paccapelo A; Pagotto U; Pasquali R
Lancet Diabetes Endocrinol; 2014 May; 2(5):396-405. PubMed ID: 24795253
[TBL] [Abstract][Full Text] [Related]
30. Hair cortisol and endocannabinoid measurement in patients with adrenal incidentalomas: a case-control study.
Mytareli C; Athanasouli F; Andreadaki E; Thanasoula F; Angelousi A
Hormones (Athens); 2024 Mar; 23(1):113-120. PubMed ID: 37792214
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and phenotype of primary bilateral macronodular adrenal hyperplasia with autonomous cortisol secretion: a study of 98 patients.
Bengoa-Rojano N; Fernández-Argüeso M; Botella-Carretero JI; Pascual-Corrales E; Araujo-Castro M
Rev Clin Esp (Barc); 2022 Oct; 222(8):458-467. PubMed ID: 35597729
[TBL] [Abstract][Full Text] [Related]
32. Depression: another cortisol-related comorbidity in patients with adrenal incidentalomas and (possible) autonomous cortisol secretion.
Šojat AS; Dunjić-Kostić B; Marina LV; Ivović M; Radonjić NV; Kendereški A; Ćirković A; Tančić-Gajić M; Arizanović Z; Mihajlović S; Vujović S
J Endocrinol Invest; 2021 Sep; 44(9):1935-1945. PubMed ID: 33528757
[TBL] [Abstract][Full Text] [Related]
33. Relationship Between Dexamethasone Suppression Test Cortisol Level >0.9 μg/dL and Depression and Quality of Life in Adrenal Incidentalomas: A Single Center Observational Case-Control Study.
Güneş M; Güneş E; Kaya Mİ; Küçükelyas HD; Barut H; Öner S
Endocr Pract; 2024 May; ():. PubMed ID: 38729569
[TBL] [Abstract][Full Text] [Related]
34. Alterations in hypothalamic-pituitary-adrenal function immediately after resection of adrenal adenomas in patients with Cushing's syndrome and others with incidentalomas and subclinical hypercortisolism.
Khawandanah D; ElAsmar N; Arafah BM
Endocrine; 2019 Jan; 63(1):140-148. PubMed ID: 30259310
[TBL] [Abstract][Full Text] [Related]
35. Association Between Mortality and Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas : A Cohort Study.
Kjellbom A; Lindgren O; Puvaneswaralingam S; Löndahl M; Olsen H
Ann Intern Med; 2021 Aug; 174(8):1041-1049. PubMed ID: 34029490
[TBL] [Abstract][Full Text] [Related]
36. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.
Rossi R; Tauchmanova L; Luciano A; Di Martino M; Battista C; Del Viscovo L; Nuzzo V; Lombardi G
J Clin Endocrinol Metab; 2000 Apr; 85(4):1440-8. PubMed ID: 10770179
[TBL] [Abstract][Full Text] [Related]
37. The association of cortisol and adrenal androgen with trabecular bone score in patients with adrenal incidentaloma with and without autonomous cortisol secretion.
Kim BJ; Kwak MK; Ahn SH; Kim JS; Lee SH; Koh JM
Osteoporos Int; 2018 Oct; 29(10):2299-2307. PubMed ID: 29971455
[TBL] [Abstract][Full Text] [Related]
38. Performance of DHEAS as a Screening Test for Autonomous Cortisol Secretion in Adrenal Incidentalomas: A Prospective Study.
Liu MS; Lou Y; Chen H; Wang YJ; Zhang ZW; Li P; Zhu DL
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1789-e1796. PubMed ID: 35137142
[TBL] [Abstract][Full Text] [Related]
39. Cortisol level after dexamethasone suppression test in patients with non-functioning adrenal incidentaloma is positively associated with the duration of reactive hyperemia response on microvascular bed.
de Paula MP; Moraes AB; de Souza MDGC; Cavalari EMR; Campbell RC; Fernandes GDS; Farias MLF; Mendonça LMC; Madeira M; Bouskela E; Kraemer-Aguiar LG; Vieira Neto L
J Endocrinol Invest; 2021 Mar; 44(3):609-619. PubMed ID: 32686043
[TBL] [Abstract][Full Text] [Related]
40. Cardiometabolic profile and urinary metabolomic alterations in non-functioning adrenal incidentalomas: A review.
Araujo-Castro M
Clin Endocrinol (Oxf); 2022 Dec; 97(6):693-701. PubMed ID: 35451056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
